155 related articles for article (PubMed ID: 23873100)
1. Prognostic value of HER-2/neu expression in epithelial ovarian cancer: a meta-analysis.
Wang Y; Wang D; Ren M
Tumour Biol; 2014 Jan; 35(1):33-8. PubMed ID: 23873100
[TBL] [Abstract][Full Text] [Related]
2. Role of HER family members in predicting prognoses in epithelial ovarian cancer: a meta-analysis.
Ouyang W; Xu L; Huang Z; Guo J; Cai J; Gao X; Wang Z
Tumori; 2015; 101(6):595-602. PubMed ID: 26045112
[TBL] [Abstract][Full Text] [Related]
3. Effect of HER-2/neu overexpression on chemoresistance and prognosis in ovarian carcinoma.
Sasaki N; Kudoh K; Kita T; Tsuda H; Furuya K; Kikuchi Y
J Obstet Gynaecol Res; 2007 Feb; 33(1):17-23. PubMed ID: 17212661
[TBL] [Abstract][Full Text] [Related]
4. Lack of effects of HER-2/neu on prognosis in colorectal cancer: a meta-analysis.
Han J; Meng QY; Liu X; Xi QL; Zhuang QL; Wu GH
Asian Pac J Cancer Prev; 2014; 15(14):5551-6. PubMed ID: 25081663
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and significance of HER-2/neu expression in early epithelial ovarian cancer.
Rubin SC; Finstad CL; Federici MG; Scheiner L; Lloyd KO; Hoskins WJ
Cancer; 1994 Mar; 73(5):1456-9. PubMed ID: 7906607
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: a multivariate analysis.
Rubin SC; Finstad CL; Wong GY; Almadrones L; Plante M; Lloyd KO
Am J Obstet Gynecol; 1993 Jan; 168(1 Pt 1):162-9. PubMed ID: 8093588
[TBL] [Abstract][Full Text] [Related]
7. Preoperative neutrophil-to-lymphocyte ratio is a predictor of survival of epithelial ovarian cancer: a systematic review and meta-analysis of observational studies.
Yang Z; Gu JH; Guo CS; Li XH; Yang WC
Oncotarget; 2017 Jul; 8(28):46414-46424. PubMed ID: 28423365
[TBL] [Abstract][Full Text] [Related]
8. Frequency of Her2/Neu Protein Expression in Ovarian Epithelial Cancers.
Jafri A; Rizvi S
J Coll Physicians Surg Pak; 2017 Sep; 27(9):544-546. PubMed ID: 29017668
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of KIF2A and HER2-Neu Overexpression in Patients With Epithelial Ovarian Cancer.
Wang D; Zhu H; Ye Q; Wang C; Xu Y
Medicine (Baltimore); 2016 Feb; 95(8):e2803. PubMed ID: 26937910
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of HER-2/neu expression in epithelial ovarian cancer: a systematic review and meta-analysis.
Wang K; Guan C; Yu J; Jin X; Sun L; Zheng L; Xia L; Zhang Y
Oncotarget; 2017 Sep; 8(43):75528-75543. PubMed ID: 29088888
[TBL] [Abstract][Full Text] [Related]
11. Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis.
de Graeff P; Crijns AP; de Jong S; Boezen M; Post WJ; de Vries EG; van der Zee AG; de Bock GH
Br J Cancer; 2009 Jul; 101(1):149-59. PubMed ID: 19513073
[TBL] [Abstract][Full Text] [Related]
12. [Overexpression and prognostic value of p53 and HER2/neu proteins in benign ovarian tissue and in ovarian cancer].
Coronado Martín PJ; Fasero Laiz M; García Santos J; Ramírez Mena M; Vidart Aragón JA
Med Clin (Barc); 2007 Jan; 128(1):1-6. PubMed ID: 17266884
[TBL] [Abstract][Full Text] [Related]
13. The prognostic and predictive value of immunohistochemically detected HER-2/neu overexpression in 361 patients with ovarian cancer: a multicenter study.
Riener EK; Arnold N; Kommoss F; Lauinger S; Pfisterer J
Gynecol Oncol; 2004 Oct; 95(1):89-94. PubMed ID: 15385115
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in gastric cancer: a meta-analysis.
Peng L; Zhan P; Zhou Y; Fang W; Zhao P; Zheng Y; Xu N
Mol Biol Rep; 2012 Oct; 39(10):9473-84. PubMed ID: 22729879
[TBL] [Abstract][Full Text] [Related]
15. Obesity and epithelial ovarian cancer survival: a systematic review and meta-analysis.
Bae HS; Kim HJ; Hong JH; Lee JK; Lee NW; Song JY
J Ovarian Res; 2014; 7():41. PubMed ID: 24834130
[TBL] [Abstract][Full Text] [Related]
16. HER-2 expression in biopsy and surgical specimen on prognosis of osteosarcoma: A systematic review and meta-analysis of 16 studies.
Zhang Q; Liu F; Wang B; Li Z; Zhou D; Yang Q; Dong J; Li J
Medicine (Baltimore); 2016 Jun; 95(23):e3661. PubMed ID: 27281068
[TBL] [Abstract][Full Text] [Related]
17. Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer.
Love RR; Duc NB; Havighurst TC; Mohsin SK; Zhang Q; DeMets DL; Allred DC
J Clin Oncol; 2003 Feb; 21(3):453-7. PubMed ID: 12560434
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany.
Pfisterer J; Du Bois A; Bentz EK; Kommoss F; Harter P; Huober J; Schmalfeldt B; Burchardi N; Arnold N; Hilpert F
Int J Gynecol Cancer; 2009 Jan; 19(1):109-15. PubMed ID: 19258951
[TBL] [Abstract][Full Text] [Related]
19. Comparison of prognoses according to non-positive and positive spectrin αII expression detected immunohistochemically in epithelial ovarian carcinoma: a retrospective study.
Maeda O; Miyata-Takata T; Shibata K; Kajiyama H; Mizuno M; Tamakoshi K; Shimoyama Y; Nakamura S; Kikkawa F
Cancer Med; 2016 Jun; 5(6):1081-92. PubMed ID: 26993048
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer.
Berchuck A; Kamel A; Whitaker R; Kerns B; Olt G; Kinney R; Soper JT; Dodge R; Clarke-Pearson DL; Marks P
Cancer Res; 1990 Jul; 50(13):4087-91. PubMed ID: 1972347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
